Drug utilisation study of antidiabetic medication during 2012-2019 in Romania.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
05
08
2021
received:
07
04
2021
accepted:
30
08
2021
pubmed:
3
9
2021
medline:
20
10
2022
entrez:
2
9
2021
Statut:
ppublish
Résumé
To analyse the antidiabetic medication (ADM) market trends in Romania and to describe the utilisation of the new ADMs (glucagon-like peptide-1 receptor agonists [GLP-1 RA], dipeptidyl peptidase-4 inhibitors [DPP-4i] and sodium-glucose transport protein 2 inhibitors [SGLT-2i]). We conducted an analysis of pharmacy claims data from IQVIA Romania. We analysed the reimbursed prescriptions that included at least one ADM as defined daily doses (DDDs)/1000 inhabitants/day and the number of prescriptions. The total number of ADMs DDDs/1000/day increased by 54.33% from 2012 (48.08) to 2019 (74.20). Biguanides, sulfonylureas and insulin were the most prescribed each year, with an increasing utilisation trend. In 2019 metformin represented 37.69% of the total market share, followed by sulfonylureas (29.94%) and insulin (23.93%). The newer antidiabetics uptake was low. In 2019 the number of DDDs/1000 inhabitants/day was 2.03 for DDP-4i, 2.39 for GLP-1 RA and 1.6 for SGLT2i. An overall trend of market increase was found for ADMs from 2012 to 2019, corresponding to the increasing prevalence of diabetes in Romania. Although the use of DPP-4i, GLP-1 RA and SGLT2i have increased steadily, the uptake remained low, with no more than 12.61% of the market share (alone or as fixed combinations with metformin or insulin) in 2019.
Sections du résumé
BACKGROUND
BACKGROUND
To analyse the antidiabetic medication (ADM) market trends in Romania and to describe the utilisation of the new ADMs (glucagon-like peptide-1 receptor agonists [GLP-1 RA], dipeptidyl peptidase-4 inhibitors [DPP-4i] and sodium-glucose transport protein 2 inhibitors [SGLT-2i]).
METHODS
METHODS
We conducted an analysis of pharmacy claims data from IQVIA Romania. We analysed the reimbursed prescriptions that included at least one ADM as defined daily doses (DDDs)/1000 inhabitants/day and the number of prescriptions.
RESULTS
RESULTS
The total number of ADMs DDDs/1000/day increased by 54.33% from 2012 (48.08) to 2019 (74.20). Biguanides, sulfonylureas and insulin were the most prescribed each year, with an increasing utilisation trend. In 2019 metformin represented 37.69% of the total market share, followed by sulfonylureas (29.94%) and insulin (23.93%). The newer antidiabetics uptake was low. In 2019 the number of DDDs/1000 inhabitants/day was 2.03 for DDP-4i, 2.39 for GLP-1 RA and 1.6 for SGLT2i.
CONCLUSIONS
CONCLUSIONS
An overall trend of market increase was found for ADMs from 2012 to 2019, corresponding to the increasing prevalence of diabetes in Romania. Although the use of DPP-4i, GLP-1 RA and SGLT2i have increased steadily, the uptake remained low, with no more than 12.61% of the market share (alone or as fixed combinations with metformin or insulin) in 2019.
Substances chimiques
Dipeptidyl-Peptidase IV Inhibitors
0
Glucagon-Like Peptide-1 Receptor
0
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14770Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Federation ID. IDF diabetes atlas ninth edition 2019. 463 million people living with diabetes [Internet]. 2019. https://www.diabetesatlas.org/upload/resources/material/20200302_133351_IDFATLAS9e-final-web.pdf. Accessed Nov 9, 2020.
Mota M, Popa SG, Mota E, et al. Prevalence of diabetes mellitus and prediabetes in the adult Romanian population: PREDATORR study. J Diabetes. 2016;8(3):336-344.
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-2498.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012;35(6):1364-1379.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429-442.
European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer | European Medicines Agency [Internet]. https://www.ema.europa.eu/en/news/european-medicines-agency-clarifies-opinion-pioglitazone-risk-bladder-cancer. Accessed Nov 9, 2020.
Committee for Medicinal Products for Human Use. Avandia-H-C-268-A20-75: EPAR - Assessment Report. 2010. [Internet]. https://www.ema.europa.eu/en/medicines/human/EPAR/avandia. Accessed Jul 30, 2021
Farcas A, Balcescu T, Anghel L, Bucsa C, Mogoșan C. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012. Expert Opin Drug Saf. 2020;19(6):755-762.
HOTARARE (A) 155 30/03/2017 - Portal Legislativ [Internet]. http://legislatie.just.ro/Public/DetaliiDocumentAfis/201694. Accessed Jul 30, 2021
Ordinul comun al Ministrului Sănătăţii Publice (OMSP) şi al Preşe dintelui CNASnr. 1061/425/2006 privind aprobarea organizării şi desfăşurării Programului naţional de diabet zaharat, Monitorul Oficial, nr. 803/25 septembrie 2006. 2006.
National Institute of Statistics. Romania in figures [Internet]. https://insse.ro/cms/en/tags/romania-figures. Accessed Dec 10, 2020
Raport Național privind Starea de Sănătate a Populației României 2018.pdf.
STAREA DE SĂNĂTATE A POPULAȚIEI ROMÂNIEI. Raport Național privind Starea de Sănătate a Populației României. 2018 [Internet]. https://insp.gov.ro/sites/cnepss/wp-content/uploads/2014/11/SSPR-2018-final-2-1.pdf. Accessed Jul 30, 2021
Morgovan C, Cosma SA, Valeanu M, et al. An exploratory research of 18 years on the economic burden of diabetes for the Romanian national health insurance system. Int J Environ Res Public Health. 2020;17(12):1-16.
WHO/Europe. Diabetes - Data and statistics [Internet]. https://www.euro.who.int/en/health-topics/noncommunicable-diseases/diabetes/data-and-statistics. Accessed Dec 10, 2020.
CDC. National Diabetes Statistics Report 2020. Estimates of diabetes and its burden in the United States. 2020.
Patterson CC, Harjutsalo V, Rosenbauer J, et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study. Diabetol. 2018;62(3):408-417.
Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Fard HH, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promot Perspect. 2020;10(2):98-115.
Csatordai M, Benkő R, Matuz M, Bor A, Lengyel C, Doró P. Use of glucose-lowering drugs in Hungary between 2008 and 2017: the increasing use of novel glucose-lowering drug groups. Diabet Med. 2019;36(12):1612-1620.
Estonian State Agency of Medicines. Drug consumption in 2017. Sisukaart, Ravimiamet.
Sakshaug S, Strøm H, Berg Hege C, Blix S, Litleskare I, Granum T. Legemiddelforbruket i Norge 2013-2017 Drug Consumption in Norway 2013-2017.
Suomen lääketilasto. Finnish Statistics on Medicines. 2017.
Engler C, Leo M, Pfeifer B, et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012-2018. BMJ Open Diabetes Res Care. 2020;8(1):e001279.
Greiver M, Havard A, Bowles JKF, et al. Trends in diabetes medication use in Australia, Canada, England, and Scotland: a repeated cross-sectional analysis in primary care. Br J Gen Pract. 2021;71(704):E209-E218.
Ghid medical pentru îngrijirea pacienților cu diabet. 2016. http://old.ms.ro/documente/GhidDIABETZAHARAT_1185_2396.pdf
Lista protocoalelor terapeutice arpobate prin Ordinul MS/CNAS NR 1098/647/2021- IULIE 2021 [Internet]. 2021. http://old.ms.ro/documente/GhidDIABETZAHARAT_1185_2396.pdf
Lublóy Á. Factors affecting the uptake of new medicines: A systematic literature review. BMC Health Serv Res. 2014;14(1):469.
Hartley P, Shentu Y, Betz-Schiff P, et al. Efficacy and tolerability of sitagliptin compared with glimepiride in elderly patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, non-inferiority trial. Drugs Aging. 2015;32(6):469-476.
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357.
Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33(6):1300-1303.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Zeitschrift fur Gefassmedizin. 2015;373(22):2117-2128.
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130.
Marso SP, Daniels GH, Frandsen KB, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519-1529.
Wofford JL. Clinical inertia. Ann Intern Med. 2002;137(6):825-834.
Aujoulat I, Jacquemin P, Darras E, et al. Factors associated with clinical inertia: an integrative review. Adv Med Educ Pract. 2014;5:141-147.
Huitema AA, Daoust A, Anderson K, et al. Optimal usage of sacubitril/valsartan for the treatment of heart failure: the importance of optimizing heart failure care in Canada. CJC Open. 2020;2(5):321-327.
State of Health in the EU The Country Health Profile series. http://www.who.int/bulletin/disclaimer/en/. Jul 30, 2021
Jermendy G, Kiss Z, Rokszin G, Abonyi-Tóth Z, Wittmann I, Kempler P. Persistence to treatment with novel antidiabetic drugs (dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists) in people with type 2 diabetes: a nationwide cohort study. Diabetes Ther. 2018;9(5):2133-2141.
Steiner S. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Zeitschrift fur Gefassmedizin. 2016;13(1):17-18.
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-39.
Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care. 2014;37(5):1367-1374. 10.2337/dc13-2289